VivoSeq
Other

Syncope

8

Pipeline Programs

1

Active Trials

6

Companies Involved

Syncope is an early-stage landscape with 8 programs across 6 companies. The most active players are Amgen, Novartis, Takeda. 2 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

9

clinical trials

Completed7 · 78%
Unknown status1 · 11%
Not yet recruiting1 · 11%

Trial Activity

9 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)